Precision BioSciences Inc (DTIL)

[jondoeuk]

Thanks for the list. It is not long compared to the one for CD19.

No, but in the trial, patients receive two cycles of LD chemo, followed by AFM13 pre-complexed cbNKs and three weekly IV infusions of AFM13, so slightly more involved than CAR-T.

I am trying to figure out how innate engagers affect TAMs thru CD16.

The innate cell engagers bind to the CD16a receptor on NK cells and macrophages https://www.tandfonline.com/doi/full/10.1080/19420862.2019.1616506 https://www.sciencedirect.com/science/article/pii/S0006497119371605

Also, for a number of the trials they are adding either an anti-PD(L)-1 or pre-complexed cbNKs as well.